Keynote B59
Phase 1/2 Recruiting
317 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Phase 1/2 Recruiting
100 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Phase 1/2 Recruiting
234 enrolled
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/2 Recruiting
75 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Phase 1/2 Recruiting
224 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
MK-3475-03C
Phase 1/2 Recruiting
140 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1/2 Recruiting
43 enrolled
PRISM
Phase 1/2 Recruiting
40 enrolled
BrILliance
Phase 1/2 Recruiting
240 enrolled
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Phase 1/2 Recruiting
345 enrolled
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
270 enrolled
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Phase 1/2 Recruiting
100 enrolled
ModiFY
Phase 1/2 Recruiting
168 enrolled
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/2 Recruiting
126 enrolled
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
76 enrolled
DENALI-1
Phase 1/2 Recruiting
240 enrolled
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Phase 1/2 Recruiting
55 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
Phase 1/2 Recruiting
90 enrolled
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/2 Recruiting
40 enrolled
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Phase 1/2 Recruiting
170 enrolled
ADPORT-601
Phase 1/2 Recruiting
90 enrolled
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
Phase 1/2 Recruiting
28 enrolled
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
Phase 1/2 Recruiting
33 enrolled
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Phase 1/2 Recruiting
358 enrolled
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/2 Recruiting
316 enrolled
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/2 Recruiting
125 enrolled
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
110 enrolled